Protocol Ledger

NCT06987539 · Phase II · RECRUITING

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Interventional Phase II clinical trial protocol NCT06987539 sponsored by Amgen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-21 Enrollment: 15 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06987539
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)15 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06987539
Protocol FieldVerified Registry Value
NCT IdentifierNCT06987539
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment15 participants (ESTIMATED)
Registered Start Date2026-07-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06987539
Hospital Research SiteLocationSite Profile
Children's Hospital of PhiladelphiaPhiladelphia, PAOpen Hospital Dossier ->
Hospital Universitari i Politecnic La FeValencia, SpainOpen Hospital Dossier ->
John Radcliffe HospitalOxford, United KingdomOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI